Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KOSDAQ - Delayed Quote KRW

AbClon Inc. (174900.KQ)

9,590.00
+360.00
+(3.90%)
At close: 3:30:30 PM GMT+9
Loading Chart for 174900.KQ
  • Previous Close 9,230.00
  • Open 9,440.00
  • Bid 9,590.00 x --
  • Ask 9,640.00 x --
  • Day's Range 9,350.00 - 10,170.00
  • 52 Week Range 6,810.00 - 19,910.00
  • Volume 285,016
  • Avg. Volume 226,584
  • Market Cap (intraday) 167.107B
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

www.abclon.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 174900.KQ

View More

Performance Overview: 174900.KQ

Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

174900.KQ
32.08%
KOSPI Composite Index (^KS11)
5.25%

1-Year Return

174900.KQ
42.54%
KOSPI Composite Index (^KS11)
3.72%

3-Year Return

174900.KQ
37.73%
KOSPI Composite Index (^KS11)
6.62%

5-Year Return

174900.KQ
59.36%
KOSPI Composite Index (^KS11)
31.90%

Compare To: 174900.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 174900.KQ

View More

Valuation Measures

Annual
As of 4/22/2025
  • Market Cap

    160.83B

  • Enterprise Value

    156.66B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    65.95

  • Price/Book (mrq)

    5.55

  • Enterprise Value/Revenue

    66.96

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.81%

  • Return on Equity (ttm)

    -57.57%

  • Revenue (ttm)

    2.34B

  • Net Income Avi to Common (ttm)

    -16.3B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.86B

  • Total Debt/Equity (mrq)

    58.67%

  • Levered Free Cash Flow (ttm)

    -12.58B

Research Analysis: 174900.KQ

View More

Company Insights: 174900.KQ

Research Reports: 174900.KQ

View More

People Also Watch